From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

As artificial intelligence (AI) becomes ever more integrated into the world of biotechnology, one of its latest applications is the discovery and design of peptides. This is a rapidly emerging field ...

The month of September was a big one for mergers and acquisitions (M&As) in the biotech industry. There were four billion-dollar acquisitions that were the most notable. The top buyout was Danish ...

As well as being known for its historical beauty and academic excellence, Cambridge has a reputation as a leading biotech hub, forming part of the U.K.’s “Golden Triangle” with Oxford and London. This ...

Asabys Partners, a Spanish venture capital (VC) firm focused on healthcare, has rolled Aliath Bioventures (formerly Alta Life Sciences) into its platform in a move that boosts its assets under ...